⚡ Quick Summary

This study provides a comprehensive analysis of 596 AI clinical trials registered globally, revealing a significant concentration of research in China (35.6%) and a lack of international collaboration (only 8.7% of trials). The findings highlight the urgent need for more inclusive and collaborative research models in the field of artificial intelligence.

🔍 Key Details

• 📊 Dataset: 596 AI clinical trials across 62 countries
• 🌍 Geographic Distribution: China (35.6%), USA (8.5%)
• 🧬 Disease Categories: Gastroenterology (22.8%), Oncology (20.1%)
• ⚙️ Technology Application: Diagnostic Support (45.6%)
• 🤝 International Collaboration: Only 8.7% of trials involve multiple countries

🔑 Key Takeaways

• 📈 Rapid Growth: AI clinical trials have seen exponential growth since 2020.
• 🌐 Geographic Imbalance: A significant concentration of trials in China raises concerns about global health equity.
• 🧪 Thematic Concentration: Most research focuses on Gastroenterology and Oncology.
• 🔍 Diagnostic Support: This is the most common application of AI technology in clinical trials.
• ⚠️ Low Collaboration: The fragmented nature of international collaboration is alarming.
• 🌍 Implications for Equity: The imbalanced growth of AI trials could undermine the generalizability of AI technologies.
• 🔄 Need for Change: A shift towards more inclusive and transparent research models is essential.

📚 Background

The integration of artificial intelligence (AI) into clinical research is transforming the landscape of healthcare. However, the lack of a comprehensive analysis of AI clinical trials has limited our understanding of global trends and collaboration patterns. This study aims to fill that gap by systematically characterizing AI-related clinical trials registered in the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP).

🗒️ Study

Conducted on June 20, 2025, this study involved a thorough search of the WHO ICTRP, followed by a two-stage screening process. The dataset was analyzed for temporal trends, geographic distribution, disease and technology categories, and patterns of international collaboration using descriptive statistics and network analysis.

📈 Results

The analysis revealed a total of 596 AI clinical trials across 62 countries, with registrations growing exponentially since 2020. The data showed that China accounted for the largest share of trial participations at 35.6%, while the USA followed with 8.5%. The research themes were predominantly in Gastroenterology (22.8%) and Oncology (20.1%), with Diagnostic Support being the most common technology application at 45.6%. Alarmingly, only 8.7% of trials involved formal international collaboration.

🌍 Impact and Implications

The findings of this study underscore the urgent need for a fundamental shift in the approach to AI clinical trials. The extreme geographic concentration and minimal international collaboration not only threaten global health equity but also limit the generalizability of AI technologies. By fostering more inclusive, transparent, and collaborative research models, we can ensure that the benefits of AI are realized equitably for all of humanity.

🔮 Conclusion

This study highlights the rapid but imbalanced growth of AI clinical trials worldwide. The concentration of research in specific regions and the lack of collaboration pose significant challenges to the equitable distribution of AI advancements in healthcare. Moving forward, it is crucial to advocate for more inclusive research practices that can bridge these gaps and enhance the global impact of AI technologies.

💬 Your comments

What are your thoughts on the current state of AI clinical trials? How can we improve collaboration and equity in this field? 💬 Share your insights in the comments below or connect with us on social media:

• 🐦 X
• 📘 Facebook
• 🔗 LinkedIn